Skip to main content
Intermediate Technical IVT

desmopressin

Pronunciation: /dɛsmoʊˈprɛsɪn/

Also written as: DDAVP — 1-deamino-8-D-arginine vasopressin

Synthetic vasopressin analog that increases factor VIII and von Willebrand factor levels for treating mild bleeding disorders.

Full Definition

Desmopressin (DDAVP) is a synthetic analog of antidiuretic hormone that stimulates the release of factor VIII and von Willebrand factor from endothelial storage sites. It is used as first-line therapy for mild hemophilia A and most subtypes of von Willebrand disease, providing a non-blood product treatment option. The drug can be administered intravenously, subcutaneously, or intranasally, with peak effects occurring 30-60 minutes after administration. Response testing is recommended before using desmopressin for surgical procedures or significant bleeding episodes.

Usage

Usage note: Generic name preferred. DDAVP abbreviation acceptable. Include route of administration when mentioned.

In Context

  • "Desmopressin testing showed a three-fold increase in factor VIII levels after administration." — Hemophilia evaluation
  • "The patient responded well to intranasal desmopressin for epistaxis management." — Emergency department note

Also known as

DDAVP 1-deamino-8-D-arginine vasopressin

Don't confuse with

vasopressin factor VIII concentrate cryoprecipitate

Editors from these organisations have used our services since 1998

Reuters BBC Oxford University Press Penguin Random House Springer Microsoft Suncor Energy United Nations Fisher Investments IBM The Home Depot KODAK CHEVRON